Swiss National Bank increased its stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 85,358 shares of the medical research company’s stock after purchasing an additional 1,100 shares during the quarter. Swiss National Bank owned 0.13% of PRA Health Sciences worth $7,774,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Magnetar Financial LLC bought a new position in shares of PRA Health Sciences during the 3rd quarter valued at approximately $5,010,000. Fox Run Management L.L.C. bought a new position in shares of PRA Health Sciences during the 4th quarter valued at approximately $439,000. Jennison Associates LLC increased its position in shares of PRA Health Sciences by 238.6% during the 4th quarter. Jennison Associates LLC now owns 11,202 shares of the medical research company’s stock valued at $1,020,000 after purchasing an additional 7,894 shares during the last quarter. Sei Investments Co. increased its position in shares of PRA Health Sciences by 8.5% during the 3rd quarter. Sei Investments Co. now owns 15,899 shares of the medical research company’s stock valued at $1,212,000 after purchasing an additional 1,245 shares during the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of PRA Health Sciences by 12.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 463,941 shares of the medical research company’s stock valued at $35,338,000 after purchasing an additional 49,693 shares during the last quarter. 97.15% of the stock is currently owned by hedge funds and other institutional investors.
In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of the company’s stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Linda Baddour sold 67,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total value of $6,048,090.00. The disclosure for this sale can be found here. Insiders sold a total of 212,700 shares of company stock valued at $19,282,021 over the last quarter. Company insiders own 2.10% of the company’s stock.
Several research firms have recently weighed in on PRAH. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 target price on the stock in a research report on Thursday, January 11th. BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. SunTrust Banks restated a “buy” rating and set a $101.00 price objective on shares of PRA Health Sciences in a report on Friday, October 27th. Credit Suisse Group restated an “outperform” rating and set a $104.00 price objective (up previously from $101.00) on shares of PRA Health Sciences in a report on Thursday. Finally, Barclays began coverage on PRA Health Sciences in a report on Monday, December 11th. They set an “overweight” rating and a $94.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $93.15.
PRA Health Sciences Inc (NASDAQ:PRAH) opened at $86.18 on Friday. PRA Health Sciences Inc has a 1-year low of $57.72 and a 1-year high of $95.90. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $5,639.27, a price-to-earnings ratio of 65.29, a P/E/G ratio of 1.21 and a beta of 0.32.
PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.02. PRA Health Sciences had a return on equity of 23.33% and a net margin of 3.85%. The business had revenue of $568.80 million during the quarter, compared to analysts’ expectations of $543.78 million. During the same period in the prior year, the business earned $0.71 EPS. The business’s revenue for the quarter was up 37.5% compared to the same quarter last year. equities analysts expect that PRA Health Sciences Inc will post 3.97 earnings per share for the current year.
WARNING: “Swiss National Bank Has $7.77 Million Stake in PRA Health Sciences Inc (PRAH)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/24/swiss-national-bank-has-7-77-million-stake-in-pra-health-sciences-inc-prah.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.